InflaRx (IFRX) N.V.announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria, CSU, and hidradenitis suppurativa, HS, investigating the Company’s oral C5aR inhibitor, INF904.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.